Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Headlands Technologies LLC

Headlands Technologies LLC reduced its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 76.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,635 shares of the company’s stock after selling 5,199 shares during the period. Headlands Technologies LLC’s holdings in Krystal Biotech were worth $256,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. Wilmington Savings Fund Society FSB acquired a new position in Krystal Biotech during the third quarter worth $40,000. Avanza Fonder AB purchased a new position in shares of Krystal Biotech during the 4th quarter worth $119,000. KBC Group NV boosted its position in shares of Krystal Biotech by 46.3% during the 4th quarter. KBC Group NV now owns 939 shares of the company’s stock valued at $147,000 after acquiring an additional 297 shares during the last quarter. Blue Trust Inc. grew its holdings in shares of Krystal Biotech by 74.4% in the fourth quarter. Blue Trust Inc. now owns 1,015 shares of the company’s stock valued at $159,000 after purchasing an additional 433 shares during the period. Finally, US Bancorp DE increased its position in Krystal Biotech by 8.7% during the fourth quarter. US Bancorp DE now owns 1,027 shares of the company’s stock worth $161,000 after purchasing an additional 82 shares during the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Krystal Biotech Trading Down 3.8 %

KRYS stock opened at $171.30 on Friday. The business’s fifty day moving average price is $173.27 and its 200 day moving average price is $173.18. Krystal Biotech, Inc. has a 12-month low of $141.72 and a 12-month high of $219.34. The company has a market capitalization of $4.93 billion, a PE ratio of 57.29 and a beta of 0.75.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. The company had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business’s revenue for the quarter was up 116.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.30 earnings per share. Research analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Insider Buying and Selling at Krystal Biotech

In other news, CAO Kathryn Romano sold 750 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the sale, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the transaction, the insider now owns 1,463,711 shares of the company’s stock, valued at approximately $260,233,178.69. This trade represents a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

KRYS has been the subject of several analyst reports. Chardan Capital increased their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research note on Thursday, February 20th. Citigroup increased their price objective on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research report on Thursday, February 20th. HC Wainwright restated a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a research report on Friday, February 28th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Krystal Biotech in a research note on Thursday, February 20th. Finally, Jefferies Financial Group initiated coverage on Krystal Biotech in a research report on Wednesday, March 5th. They set a “buy” rating and a $245.00 price objective for the company. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $220.00.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).